ArticleBMC anesthesiology2025
Esketamine mitigates endotoxin-induced acute lung injury by suppressing caspase-11-driven pyroptosis.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pyroptosis- and Necroptosis-Related Signaling in Salicylate UV Absorber-Induced Toxicity: Implications for Sustainable Chemistry and Human Health.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcute lung injury (ALI) is a common complication of endotoxemia, which carries a high risk of morbidity and mortality. Currently, no effective drugs exist to treat endotoxin-induced ALI. This study evaluated esketamine's protective effects against endotoxin-induced ALI and explored its underlying mechanisms.
methodsCecal ligation and puncture (CLP) was used to create a rat model of endotoxin-induced ALI. Esketamine (10 mg/kg) was injected into the tail vein of rats for drug treatment. The murine sepsis score (MSS) was used to evaluate the state of rats. Hematoxylin and eosin (HE) staining was used to evaluate lung tissue morphology and calculate the lung injury scores. The degree of lung tissue edema was assessed using the wet-to-dry weight (W/D) ratio. The expressions of caspase-11 and gasdermin D (GSDMD)-N, linked to the atypital pyroptosis pathway, were examined using immunohistochemistry (IHC) and western blot (WB) analysis. Caspase-11 and GSDMD mRNA levels were determined using quantitative real-time polymerase chain reaction (qRT-PCR). The expression of PI3K/AKT pathway was assessd using western blotting analysis. Interleukin (IL)-1β levels were quantified via enzyme-linked immunosorbent assay (ELISA).
resultsEsketamine treatment improved lung tissue structure, reduced pulmonary edema, and mitigated the inflammatory response in ALI. Esketamine inhibited caspase-11 and GSDMD expressions and decreased IL-1β levels, while reversing the inhibition of the PI3K/AKT pathway in ALI.
conclusionEsketamine mitigates CLP-induced ALI by suppressing the caspase-11-GSDMD pathway and reducing inflammation. The PI3K/AKT pathway may be involved in these protective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.